TABLE 1.
Pearson's correlation | Linear regression of the slope | |||
---|---|---|---|---|
Category | r 2 | p | Slope | 95% CI |
Gender | ||||
Female (n = 44) | 0.8990 | <0.0001 | 1.031 | 0.8746 to 1.1870 |
Male (n = 40) | 0.7698 | <0.0001 | 1.808 | 1.3160 to 2.3010 |
Both (n = 11) | 0.3470 | 0.2957 | 0.748 | −0.7763 to 2.2720 |
Bone site | ||||
Tibia (n = 15) | 0.8631 | <0.0001 | 1.194 | 0.9090 to 1.4790 |
Femur (n = 63) | 0.5204 | <0.0001 | 1.690 | 1.2750 to 2.1050 |
Vertebrae (n = 21) | 0.1462 | 0.0872 | 0.620 | −0.0996 to 1.3400 |
Age at start of treatment | ||||
0–2 weeks (n = 12) | 0.4261 | 0.0214 | 0.988 | 0.1802 to 1.7970 |
4–8 weeks (n = 22) | 0.3150 | 0.0066 | 0.752 | 0.2348 to 1.2690 |
9–10 weeks (n = 23) | 0.6942 | <0.0001 | 0.950 | 0.6640 to 1.2360 |
11–12 weeks (n = 25) | 0.7071 | <0.0001 | 1.530 | 1.1050 to 1.9540 |
>12 weeks (n = 22) | 0.6239 | <0.0001 | 2.031 | 1.2950 to 2.7670 |
Days per week of treatment | ||||
5–5.5 (n = 35) | 0.8758 | <0.0001 | 1.250 | 1.0060 to 1.4940 |
7 (n = 66) | 0.6487 | <0.0001 | 1.3178 | 0.9320 to 1.7010 |
Treatment duration | ||||
<4 weeks (n = 23) | 0.6880 | <0.0001 | 1.347 | 0.9357 to 1.7590 |
4 weeks (n = 48) | 0.3858 | <0.0001 | 0.885 | 0.5335 to 1.2016 |
5–6 weeks (n = 22) | 0.6749 | <0.0001 | 2.459 | 1.6630 to 3.2550 |
7–12 weeks (n = 12) | 0.6503 | 0.0015 | 0.790 | 0.3814 to 1.1970 |
Treatment dose (μg/kg/day) | ||||
≦30 (n = 19) | 0.6201 | <0.0001 | 2.176 | 1.3050 to 3.0480 |
40 (n = 19) | 0.6799 | <0.0001 | 1.565 | 1.0150 to 2.1140 |
50–60 (n = 13) | 0.3717 | 0.0269 | 1.135 | 0.1559 to 2.1150 |
80 (n = 44) | 0.4488 | <0.0001 | 0.919 | 0.6021 to 1.2370 |
90–160 (n = 10) | 0.9454 | <0.0001 | 1.001 | 0.8050 to 1.1970 |
Notes: Data was pooled to analyze Pearson's correlation of the trabecular response of wild‐type mice to vehicle or iPTH. The r 2 and p value are reported from this analysis. The slope and 95% CI of the linear regression of the slope is also reported.
Abbreviations: CI, confidence interval; iPTH, intermittent parathyroid hormone.